Petrus Trust Company LTA Acquires 1,848 Shares of IQVIA Holdings Inc. $IQV

Key Points

• Petrus Trust Company LTA increased its stake in IQVIA Holdings Inc. by 151.1%, acquiring an additional 1,848 shares during the 1st quarter, bringing its total to 3,071 shares worth approximately $541,000.
• IQVIA's stock opened at $187.75 with a recent market capitalization of $31.92 billion, and it reported a 5.3% year-over-year revenue increase to $4.02 billion.
• Brokerages have raised their target prices for IQVIA stock, with estimates now ranging up to $225.00, reflecting a consensus rating of "Moderate Buy" among equity analysts.

Petrus Trust Company LTA lifted its stake in shares of IQVIA Holdings Inc. (NYSE:IQV - Free Report) by 151.1% during the 1st quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor owned 3,071 shares of the medical research company's stock after purchasing an additional 1,848 shares during the quarter. Petrus Trust Company LTA's holdings in IQVIA were worth $541,000 as of its most recent SEC filing.

A number of other hedge funds and other institutional investors have also bought and sold shares of IQV. Nissay Asset Management Corp Japan ADV increased its holdings in IQVIA by 0.8% in the 1st quarter. Nissay Asset Management Corp Japan ADV now owns 22,428 shares of the medical research company's stock valued at $3,954,000 after buying an additional 181 shares during the period. NewEdge Advisors LLC increased its stake in IQVIA by 13.9% in the first quarter. NewEdge Advisors LLC now owns 21,576 shares of the medical research company's stock valued at $3,804,000 after acquiring an additional 2,626 shares during the last quarter. Nippon Life Global Investors Americas Inc. raised its position in IQVIA by 9.3% during the first quarter. Nippon Life Global Investors Americas Inc. now owns 47,350 shares of the medical research company's stock valued at $8,348,000 after purchasing an additional 4,020 shares in the last quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. lifted its stake in IQVIA by 0.6% during the first quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 50,282 shares of the medical research company's stock worth $8,865,000 after purchasing an additional 281 shares during the last quarter. Finally, Invenomic Capital Management LP boosted its holdings in shares of IQVIA by 65.7% in the 1st quarter. Invenomic Capital Management LP now owns 88,062 shares of the medical research company's stock valued at $15,525,000 after purchasing an additional 34,913 shares in the last quarter. Institutional investors and hedge funds own 89.62% of the company's stock.

IQVIA Trading Up 1.2%

IQV traded up $2.21 during trading on Tuesday, reaching $189.89. 1,200,874 shares of the company's stock were exchanged, compared to its average volume of 1,160,792. The company has a current ratio of 0.84, a quick ratio of 0.84 and a debt-to-equity ratio of 2.45. IQVIA Holdings Inc. has a one year low of $134.65 and a one year high of $248.03. The firm has a fifty day moving average price of $181.03 and a two-hundred day moving average price of $167.36. The stock has a market capitalization of $32.28 billion, a PE ratio of 27.48, a price-to-earnings-growth ratio of 2.06 and a beta of 1.32.

IQVIA (NYSE:IQV - Get Free Report) last issued its quarterly earnings results on Tuesday, July 22nd. The medical research company reported $2.81 EPS for the quarter, topping analysts' consensus estimates of $2.77 by $0.04. The company had revenue of $4.02 billion for the quarter, compared to analyst estimates of $3.96 billion. IQVIA had a net margin of 7.88% and a return on equity of 30.05%. IQVIA's revenue was up 5.3% compared to the same quarter last year. During the same quarter in the previous year, the business earned $2.64 earnings per share. IQVIA has set its FY 2025 guidance at 11.750-12.050 EPS. As a group, equities research analysts forecast that IQVIA Holdings Inc. will post 10.84 earnings per share for the current fiscal year.

Insider Buying and Selling

In related news, insider Keriann Cherofsky sold 549 shares of the company's stock in a transaction that occurred on Wednesday, July 23rd. The stock was sold at an average price of $191.53, for a total value of $105,149.97. Following the sale, the insider directly owned 2,910 shares in the company, valued at $557,352.30. This represents a 15.87% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available at this hyperlink. Also, insider Eric Sherbet sold 5,800 shares of the stock in a transaction that occurred on Wednesday, July 23rd. The shares were sold at an average price of $190.05, for a total transaction of $1,102,290.00. Following the sale, the insider directly owned 27,178 shares of the company's stock, valued at $5,165,178.90. This represents a 17.59% decrease in their position. The disclosure for this sale can be found here. 1.60% of the stock is owned by insiders.

Analysts Set New Price Targets

A number of research firms have recently commented on IQV. Robert W. Baird boosted their price target on IQVIA from $159.00 to $196.00 and gave the stock a "neutral" rating in a report on Wednesday, July 23rd. Jefferies Financial Group raised IQVIA from a "hold" rating to a "buy" rating and boosted their target price for the stock from $195.00 to $225.00 in a research note on Tuesday. William Blair restated an "outperform" rating on shares of IQVIA in a research note on Wednesday, July 23rd. UBS Group lifted their price target on shares of IQVIA from $185.00 to $225.00 and gave the company a "buy" rating in a report on Wednesday, July 23rd. Finally, Citigroup reissued a "neutral" rating on shares of IQVIA in a research note on Thursday, May 22nd. Eighteen research analysts have rated the stock with a Buy rating and six have issued a Hold rating to the company's stock. According to MarketBeat, IQVIA has a consensus rating of "Moderate Buy" and an average target price of $229.64.

IQVIA Profile

IQVIA Holdings Inc engages in the provision of advanced analytics, technology solutions, and clinical research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions.